Patents
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
06/2013
06/13/2013WO2013043032A3 Dialysed extract of leucocytes from shark spleen, for obtaining a transfer factor with increased potential, specifically designed to be used as an immunomodulator, and method for extracting, checking and counting same
06/13/2013WO2013041692A3 Method to predict the presence of inflammation or itaconic acid, irg1 and/or protein irg1 in a subject and pharmaceutical composition for treating or preventing inflammation
06/13/2013WO2013032248A3 Composition for improving skin conditions, containing extracellular domain of human bone morphogenetic protein receptor 1a as active ingredient
06/13/2013WO2013025064A3 Anti-cancer composition comprising wnt decoy receptors
06/13/2013WO2013018097A3 Novel sequences for the control of reproduction in fish
06/13/2013WO2013015668A3 Use of the peptide gk-1 expressed in the filamentous phage m13 for preparing pharmaceutical products that increase the effectiveness of the immune response induced by vaccine antigens or pathogens
06/13/2013WO2013009910A3 Eosinophil peroxidase compositions and methods of their use
06/13/2013WO2012162565A3 Method for inducing an immune response for treatment of cancer and autoimmune diseases or conditions
06/13/2013WO2011163650A3 Methods and compositions for cns delivery of arylsulfatase a
06/13/2013WO2011133960A9 Lysosomal storage disease enzyme
06/13/2013US20130150649 Sensitization of tumor cells to radiation therapy through administration of endothelin agonists
06/13/2013US20130150555 Composition containing inducer of sirt1 expression for preventing or treating sepsis or septic shock
06/13/2013US20130150432 Efficacy of cancer therapy
06/13/2013US20130150311 Mixed poloxamer excipients
06/13/2013US20130150310 Compositions and Methods for Treatment of Cancer
06/13/2013US20130150309 Cyclized peptidomimetic small molecule inhibitors of the wdr5 and mll1 interaction
06/13/2013US20130150307 Injection paradigm for administration of botulinum toxins
06/13/2013US20130150306 Milk-based nutritional compositions containing lactoferrin and uses thereof
06/13/2013US20130150304 Treatment of a disease associated with retinal degenerative disorder
06/13/2013US20130150302 Conjugated blood coagulation factor viii
06/13/2013US20130150301 Therapeutic agents for regulating serum phosphorus
06/13/2013US20130150299 Template-fixed peptidomimetics
06/13/2013US20130150298 Parstatin peptides
06/13/2013US20130150296 Albumin fusion proteins
06/13/2013US20130150295 Sustained-Release Formulations Comprising Crystals, Macromolecular Gels, and Particulate Suspensions of Biologic Agents
06/13/2013US20130150293 Method for preventing and treating diabetes using neurturin
06/13/2013US20130150292 Soft Protease Inhibitors and Pro-Soft Forms Thereof
06/13/2013US20130150288 Treatment of viral infections
06/13/2013US20130150286 Methods and pharmaceutical compositions for the treatment of respiratory tract infections
06/13/2013US20130150285 Therapeutic and cosmetic uses and applications of calreticulin
06/13/2013US20130150284 Immobilized biologically active entities having a high degree of biological activity
06/13/2013US20130149744 Methods for Producing a Fusion Protein Capable of Binding VEGF
06/13/2013US20130149719 Proteins Expressed by Mycobacterium Tuberculosis and not by BCG and Their Use as Diagnostic Reagents
06/13/2013US20130149356 Muscle-based grafts/implants
06/13/2013US20130149343 Hemostatic Bioabsorbable Device with Polyethylene Glycol Binder
06/13/2013US20130149334 Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof
06/13/2013US20130149321 Candidates against infection
06/13/2013US20130149320 Asf1b as a Prognosis Marker and Therapeutic Target in Human Cancer
06/13/2013US20130149314 p19Arf, HMGA2 and MDM2 For Use in the Diagnosis and Treatment of Aberrant Cell Growth
06/13/2013US20130149311 Gfi1b modulation and uses thereof
06/13/2013US20130149307 Humanized anti-egfl7 antibodies and methods using same
06/13/2013US20130149306 Antagonists of Sema3E/PlexinD1 interaction as anti-cancer agents
06/13/2013US20130149299 Dosages for treatment with anti-egfr antibodies
06/13/2013US20130149295 Furin and biologically active derivatives thereof for use in the prevention or treatment of an inflammatory disease
06/13/2013US20130149294 Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects
06/13/2013US20130149293 Stable compositions of factor ix
06/13/2013US20130149292 Thrombin-free biological adhesive and use thereof as a medicament
06/13/2013US20130149285 Adipose tissue-derived stem cells for veterinary use
06/13/2013US20130149281 Organic compounds and their uses
06/13/2013US20130149280 Preparative regimen for engraftment, growth and differentiation of non-hematopoeitic cells in vivo after transplantation
06/13/2013DE102011122236A1 Composition useful e.g. in topical treatment of inflammatory diseases of skin and/or mucous membrane, comprises fusafungine and its derivate, and acidic glycosaminoglycan or its derivatives
06/13/2013CA2858550A1 Aromatic-cationic peptides and uses of same
06/13/2013CA2858379A1 Osteopontin variants for use in suppression or prevention of tumor growth and compositions containing such osteopontin variants
06/13/2013CA2858148A1 Methods and products for transfecting cells
06/13/2013CA2857982A1 Robust controlled-release peptide formulations
06/13/2013CA2857686A1 Use of growth hormone fragments
06/13/2013CA2857250A1 Compositions for preventing or treating adverse reactions of egfr inhibition
06/13/2013CA2855122A1 Modified mini-hepcidin peptides and methods of using thereof
06/13/2013CA2852365A1 New proteases able to hydrolyze gluten peptides and proteins at acidic ph, from the actinomycete actinoallomurus
06/13/2013CA2762338A1 Therapy for subarachnoid hemorrhage and ischemia
06/12/2013EP2601966A1 Treatment of neurological or neurodegenerative disorders
06/12/2013EP2601965A1 Compositions for preventing or treating adverse reactions of EGFR inhibition
06/12/2013EP2601964A1 Balanol compounds for use in treating pain
06/12/2013EP2601963A1 N-isovaleroyl-l-glutamyl-l-tryptophan as an agent inhibiting the formation of ulcers in the stomach and the duodenum
06/12/2013EP2601962A1 Use of Recombinant LAG-3 or the Derivatives Thereof for Eliciting Monocyte Immune Response
06/12/2013EP2601961A1 Use of Recombinant LAG-3 or the Derivatives Thereof for Eliciting Monocyte Immune Response
06/12/2013EP2601934A1 Vesicular phospholipid gels comprising proteinaceous substances
06/12/2013EP2601932A1 Lyophilized recombinant VWF formulations
06/12/2013EP2601530A2 Compositions and methods for detecting, diagnosing, and treating cancer
06/12/2013EP2601210A1 Improved recombinant human follicle-stimulating hormone
06/12/2013EP2600901A2 Engineered nucleic acids and methods of use thereof
06/12/2013EP2600896A2 Treating breast cancer with anti-il-19 antibody
06/12/2013EP2600888A2 Novel compounds as dpp-iv inhibitors and process for preparation thereof
06/12/2013EP2600887A2 Microcrystalline y receptor agonists
06/12/2013EP2600886A1 Use of a peptide enhancing the ability of radiation therapy to kill cancer cells
06/12/2013EP2600885A2 Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases
06/12/2013EP2600884A2 Polypeptides for treating and/or limiting influenza infection
06/12/2013EP2600883A1 Composition comprising glutathione reductase and oxidized glutathione, and therapeutic uses thereof
06/12/2013EP2600882A1 Antibodies against 6-sulfo-lacnac-positive human dendritic cells, and their use
06/12/2013EP2600855A2 Combination therapy for the treatment of prostate carcinoma
06/12/2013EP2600843A2 Therapeutic protein compositions having reduced immunogenicity and/or improved efficacy
06/12/2013CN1942588B Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
06/12/2013CN1922332B Methods for predicting and overcoming resistance to chemotherapy in ovarian cancer and for predicting colon cancer occurrence
06/12/2013CN1812804B Selective r-cadherin antagonist and methods
06/12/2013CN1529753B Disease-associated protein
06/12/2013CN1461310B ANtibodies that bind human interleukin-18 and methods of making and using
06/12/2013CN103154024A Novel N-terminally modified insulin derivatives
06/12/2013CN103153344A Methods, compositions, and kits for the treatment of matrix mineralization disorders
06/12/2013CN103153340A Treatment for neoplastic diseases
06/12/2013CN103153337A Mucosal adjuvant composition
06/12/2013CN103153335A Small-molecule-targeted protein degradation
06/12/2013CN103153334A New emd formulation comprising pga
06/12/2013CN103153333A Method for purification of complement factor H
06/12/2013CN103153332A Compositions and methods for treatment of hematological malignancies
06/12/2013CN103153331A Humanized antibodies targeting the EC1 domain of cadherin-11 and related compositions and methods
06/12/2013CN103153330A Novel cyclosporin derivatives for the treatment and prevention of a viral infection
06/12/2013CN103153329A Novel cyclosporin derivatives for the treatment and prevention of a viral infection
06/12/2013CN103153328A Peptide for use in the treatment of breast cancer and/or bone metastases
06/12/2013CN103153327A Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof
06/12/2013CN103153326A Peptides containing tryptophan